6533b823fe1ef96bd127e15a
RESEARCH PRODUCT
Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index
Daniela IaconoFrancesco CicciaGiuseppe ScaliseEnnio Giulio FavalliFrancesco CasoLuisa CostaIlenia PantanoRaffaele ScarpaGiuliana Gugginosubject
0301 basic medicineTreatment responsemedicine.medical_specialtypsoriatic arthritiInflammatory arthritisImmunologyDMARDs (biologic)urologic and male genital diseasestreatment.General Biochemistry Genetics and Molecular Biology03 medical and health sciencesPsoriatic arthritis0302 clinical medicineRheumatologyInternal medicinemedicineImmunology and AllergyIn patient030203 arthritis & rheumatologytreatmentbusiness.industryInterleukinmedicine.diseaseObesity030104 developmental biologySecukinumabbusinessBody mass indexdescription
We read with interest the recently published paper from McGonagle et al 1 analysing the role of interleukin (IL)-17A in axial spondyloarthritis and psoriatic arthritis (PsA). The meta-analysis and functional study provided by the authors highlighted the efficacy of IL-17A block by secukinumab in the treatment of PsA. However, there is no mention of the role of body mass index (BMI), if any, in influencing the clinical response to secukinumab, given the lack of published data. PsA is a chronic inflammatory arthritis burdened by a series of metabolic comorbidities. Among them, obesity is very common in PsA, with a prevalence of 27%, as confirmed by a recent Spanish work.2 Obesity in PsA has been associated with higher disease activity and a worse effectiveness of biologic treatment in PsA. This has been certainly proven for anti-tumour necrosis factor (TNF)-α as demonstrated by different studies reporting, in obese patients, a reduced treatment response and adherence. In particular, …
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-03-13 |